UPC CFI 616/2025

Vor dem UPC: GlaxoSmithKline Biologicals SA (20 Verfahren)·Moderna Group (20 Verfahren)

• 2026-09-14
  InfringementÖffentlich

  Zusammenfassung: The Hague Local Division panel order (11 Sep 2026) in GlaxoSmithKline Biologicals SA v Moderna Netherlands B.V. and fourteen Moderna affiliates (EP 2 590 626; infringement action UPC_CFI_616/2025 and counterclaim for revocation UPC_CFI_1439/2025): after the oral hearing of 1 Sep 2026, the panel revokes under R. 335 RoP the judge-rapporteur's earlier rejection of GSK's late-filed 'New ATEM' cryo-TEM reports with stained RNA of the accused products, admits them, orders GSK to resubmit them with a 600-word explanation by 16 Sep 2026 and lets Moderna respond within one week; the target decision date is unaffected.

  Rechtsfragen anzeigen (3)

  • Revocation of a judge-rapporteur's case management order by the panel (R. 331.3, 334, 335 RoP)
  • Admission of late-filed evidence after the oral hearing; right to be heard (Art. 76(2) UPCA)
  • R. 114 RoP exceptional case
• 2026-02-18
  Infringement ActionÖffentlich

  Zusammenfassung: The Hague Local Division ruled on GSK's application to amend its claim under Rule 263 RoP and Moderna's application to dismiss late-filed submissions under Rule 9 RoP in patent infringement proceedings relating to mRNA vaccine technology.

  Rechtsfragen anzeigen (3)

  • Amendment of claim Rule 263 RoP
  • Late-filed submissions Rule 9 RoP
  • mRNA vaccine patent